Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 9/20 | 0.66 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.37 |
| ▸ | WNT3A | P56704 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25477702 | 1.00 | HTR1B (0.66) | HTR1BCYP2A6CA2CTNNB1WNT3A | |
| SCHEMBL25477690 | 1.00 | HTR1B (0.66) | HTR1BCYP2A6CA2CTNNB1WNT3A | |
| SCHEMBL25477692 | 0.87 | HTR1B (0.66) | HTR1BCYP2A6 | |
| SCHEMBL25477711 | 0.87 | HTR1B (0.66) | HTR1BCYP2A6 | |
| SCHEMBL25477704 | 0.87 | HTR1B (0.66) | HTR1BCYP2A6 | |
| SCHEMBL13747619 | 0.85 | HTR1B (0.68) | HTR1BCYP2A6CA2CTNNB1WNT3A | |
| SCHEMBL1602504 | 0.84 | HTR1B (0.71) | HTR1BCYP2A6CTNNB1WNT3ADYRK1A | |
| SCHEMBL8008472 | 0.82 | HTR1B (0.64) | HTR1BCYP2A6CA2CTNNB1WNT3A | |
| SCHEMBL25742643 | 0.82 | HTR1B (0.64) | HTR1BCYP2A6CA2CTNNB1WNT3A | |
| SCHEMBL25237253 | 0.81 | HTR1B (0.67) | HTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767305-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230150963-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC. (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767305-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | BDNF, CREBBP, ELF3 | HTR1B 273/4885CYP2A6 884/4885CA2 4117/4885 |
| US-20230150963-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | BDNF, CREBBP, ELF3 | HTR1B 273/4885CYP2A6 884/4885CA2 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.